A Novel Mutation Affecting the Interdomain Link Region of the Growth Hormone Receptor in a Vietnamese Girl, and Response to Long-Term Treatment with Recombinant Human Insulin-Like Growth Factor-I and Luteinizing Hormone-Releasing Hormone Analogue

1998 ◽  
Vol 83 (7) ◽  
pp. 2554-2561 ◽  
Author(s):  
J. L. Walker
The Lancet ◽  
2001 ◽  
Vol 358 (9295) ◽  
pp. 1754-1759 ◽  
Author(s):  
Aart Jan van der Lely ◽  
R Kent Hutson ◽  
Peter J Trainer ◽  
G Michael Besser ◽  
Ariel L Barkan ◽  
...  

2000 ◽  
Vol 80 (2) ◽  
pp. 373-376 ◽  
Author(s):  
S. Horth ◽  
C. Farmer

Pregnant gilts received a placebo (CTL; n = 7) or 10 mg of bromocriptine orally (Bromo; n = 7) thrice daily from days 70 to 107 of gestation. Blood profiles of prolactin (PRL), growth hormone (GH) and cortisol were obtained on day 70, after the first treatment with bromocriptine, and on day 107 of gestation. On day 70, concentrations of PRL, GH and cortisol were not affected (P > 0.1) by bromocriptine. By day 107, bromocriptine decreased concentrations of PRL (P < 0.01) whereas concentrations of GH and cortisol were not affected (P > 0.1). Results indicate that long-term treatment with bromocriptine inhibits PRL secretion without affecting GH and cortisol concentrations, while no changes are present within 8 h of initial treatment. Key words: Gilt, gestation, bromocriptine, prolactin


Sign in / Sign up

Export Citation Format

Share Document